(MAGN) Magnera placeholder - NYSE
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 437m USD | Total Return: -4.4% in 12m
Avg Turnover: 3.61M
Qual. Beats: 0
Rev. Trend: 88.5%
Warnings
High Debt/EBITDA (5.3) with thin interest coverage (0.9)
Interest Coverage Ratio 0.9 is critical
Choppy
Tailwinds
No distinct edge detected
Magnera Corporation (NYSE: MAGN) is a global manufacturer of non-woven materials and specialty products, primarily serving the healthcare, personal care, and consumer goods sectors. Headquartered in Charlotte, North Carolina, the company produces essential components for medical garments, filtration systems, hygiene products, and household items like dryer sheets and coffee filters.
The non-woven industry relies on specialized engineered fabrics created through mechanical, thermal, or chemical bonding rather than traditional weaving. This business model focuses on high-volume supply chains where consistent material performance is critical for disposable consumer staples and medical safety standards.
For a detailed analysis of the companys financial health and valuation, consider reviewing the latest data on ValueRay.
- Global demand for personal care hygiene products drives core revenue growth
- Raw material cost fluctuations impact manufacturing margins and bottom-line profitability
- Healthcare sector volume shifts dictate medical garment and filtration sales performance
- Expansion into emerging markets increases consumer solution segment market share
- Interest rate volatility affects debt servicing for capital-intensive manufacturing operations
| Net Income: -110.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 3.81 > 1.0 |
| NWC/Revenue: 24.56% < 20% (prev 38.03%; Δ -13.48% < -1%) |
| CFO/TA 0.05 > 3% & CFO 185.0m > Net Income -110.0m |
| Net Debt (1.70b) to EBITDA (321.0m): 5.31 < 3 |
| Current Ratio: 2.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.9m) vs 12m ago 0.84% < -2% |
| Gross Margin: 9.95% > 18% (prev 10.57%; Δ -0.62% > 0.5%) |
| Asset Turnover: 82.09% > 50% (prev 53.87%; Δ 28.22% > 0%) |
| Interest Coverage Ratio: 0.86 > 6 (EBIT TTM 126.0m / Interest Expense TTM 146.0m) |
| A: 0.21 (Total Current Assets 1.41b - Total Current Liabilities 605.0m) / Total Assets 3.90b |
| B: -0.05 (Retained Earnings -211.0m / Total Assets 3.90b) |
| C: 0.03 (EBIT TTM 126.0m / Avg Total Assets 3.98b) |
| D: 0.36 (Book Value of Equity 1.04b / Total Liabilities 2.86b) |
| Altman-Z'' = 1.77 = BBB |
| DSRI: 0.73 (Receivables 536.0m/492.0m, Revenue 3.27b/2.19b) |
| GMI: 1.06 (GM 10.57% / 9.95%) |
| AQI: 1.01 (AQ_t 0.26 / AQ_t-1 0.26) |
| SGI: 1.49 (Revenue 3.27b / 2.19b) |
| TATA: -0.08 (NI -110.0m - CFO 185.0m) / TA 3.90b) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of June 15, 2026, the stock is trading at USD 12.63 with a total of 332,106 shares traded.
Over the past week, the price has changed by +12.57%,
over one month by +19.49%,
over three months by +16.51% and
over the past year by -4.39%.
Magnera placeholder has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold MAGN.
- StrongBuy: 0
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.5 | 14.8% |
P/E Forward = 13.6986
P/S = 0.1339
P/B = 0.4109
P/EG = 4.2261
Revenue TTM = 3.27b USD
EBIT TTM = 126.0m USD
EBITDA TTM = 321.0m USD
Long Term Debt = 1.94b USD (estimated: total debt 1.96b - short term 17.0m)
Short Term Debt = 17.0m USD (from shortTermDebt, last quarter)
Debt = 2.01b USD (from shortLongTermDebtTotal, last quarter) + Leases 48.0m
Net Debt = 1.70b USD (calculated: Debt 2.01b - CCE 303.0m)
Enterprise Value = 2.14b USD (437.2m + Debt 2.01b - CCE 303.0m)
Interest Coverage Ratio = 0.86 (Ebit TTM 126.0m / Interest Expense TTM 146.0m)
EV/FCF = 16.73x (Enterprise Value 2.14b / FCF TTM 128.0m)
FCF Yield = 5.98% (FCF TTM 128.0m / Enterprise Value 2.14b)
FCF Margin = 3.92% (FCF TTM 128.0m / Revenue TTM 3.27b)
Net Margin = -3.37% (Net Income TTM -110.0m / Revenue TTM 3.27b)
Gross Margin = 9.95% ((Revenue TTM 3.27b - Cost of Revenue TTM 2.94b) / Revenue TTM)
Gross Margin QoQ = 10.43% (prev 10.86%)
Tobins Q-Ratio = 0.55 (Enterprise Value 2.14b / Total Assets 3.90b)
Interest Expense / Debt = 7.27% (Interest Expense 146.0m / Debt 2.01b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 99.5m (EBIT 126.0m * (1 - 21.00%))
Current Ratio = 2.33 (Total Current Assets 1.41b / Total Current Liabilities 605.0m)
Debt / Equity = 1.93 (Debt 2.01b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = 5.31 (Net Debt 1.70b / EBITDA 321.0m)
Debt / FCF = 13.31 (Net Debt 1.70b / FCF TTM 128.0m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.76% (Net Income -110.0m / Total Assets 3.90b)
RoE = -10.30% (Net Income TTM -110.0m / Total Stockholder Equity 1.07b)
RoCE = 4.19% (EBIT 126.0m / Capital Employed (Equity 1.07b + L.T.Debt 1.94b))
RoIC = 3.17% (NOPAT 99.5m / Invested Capital 3.14b)
WACC = 7.05% (E(437.2m)/V(2.44b) * Re(13.03%) + D(2.01b)/V(2.44b) * Rd(7.27%) * (1-Tc(0.21)))
Discount Rate = 13.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.81 | Cagr: 1.50%
[DCF] Terminal Value 75.44% ; FCFF base≈128.0m ; Y1≈128.5m ; Y5≈136.2m
[DCF] Fair Price = 11.62 (EV 2.12b - Net Debt 1.70b = Equity 413.6m / Shares 35.6m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.47 | # QB: 0
Revenue Correlation: 88.52 | Revenue CAGR: 46.58% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.12 | Chg30d=-29.41% | Revisions=-20% | Analysts=1
EPS current Year (2026-09-30): EPS=-0.94 | Chg30d=-36.23% | Revisions=-20% | GrowthEPS=+79.0% | GrowthRev=+5.6%
EPS next Year (2027-09-30): EPS=1.68 | Chg30d=+79.01% | Revisions=+20% | GrowthEPS=+927.3% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: -20%